Vaccines for the kids! Here's all you need to know about it.
The COVID-19 vaccine, developed by Pfizer and BioNTech, is the first and only vaccination authorised for children aged 12 to 15. Children should get the same dosage as adults, with two injections given three weeks apart (21 days). In Phase-3 research including 2,260 children, the vaccination was shown to be 100 per cent efficacious. The CDC is keeping an eye on reports of myocarditis (heart muscle inflammation) and pericarditis in adolescents and young adults following immunisation. The Pfizer vaccination for youngsters aged 12 to 15 received approval from the european Medicines Agency (EMA). The company is testing its vaccine on youngsters aged 6 months to 11 years old.
In India, only three COVID-19 vaccines have been licenced for usage. None of these, however, are approved for use in anyone under the age of 18. indian versions of Russian vaccinations include Covaxin, Covishield, and Sputnik V. Bharat Biotech has received approval for a phase 2-3 clinical study of its Covaxin vaccine. The experiment will be undertaken on youngsters aged two to eighteen. The multicenter, open-label trial will assess safety, reactogenicity, and immunogenicity.
WHO: Clinical trials are underway for eight intranasal vaccines in the US, UK, China, India, iran and Cuba. Mucosal vaccines could create a strong immune response and stop the virus at the initial entry point (the nasopharyngeal mucosa) These vaccines could also cut down transmission of the virus by reducing viral shedding. However, closer proximity to the brain also raises some serious safety concerns. Reports of increased risk of Bell's Palsy had led to the discontinuation of Berna Biotech's inactivated intranasal influenza vaccine in the past.
In India, only three COVID-19 vaccines have been licenced for usage. None of these, however, are approved for use in anyone under the age of 18. indian versions of Russian vaccinations include Covaxin, Covishield, and Sputnik V. Bharat Biotech has received approval for a phase 2-3 clinical study of its Covaxin vaccine. The experiment will be undertaken on youngsters aged two to eighteen. The multicenter, open-label trial will assess safety, reactogenicity, and immunogenicity.
WHO: Clinical trials are underway for eight intranasal vaccines in the US, UK, China, India, iran and Cuba. Mucosal vaccines could create a strong immune response and stop the virus at the initial entry point (the nasopharyngeal mucosa) These vaccines could also cut down transmission of the virus by reducing viral shedding. However, closer proximity to the brain also raises some serious safety concerns. Reports of increased risk of Bell's Palsy had led to the discontinuation of Berna Biotech's inactivated intranasal influenza vaccine in the past.